electroCore (NASDAQ:ECOR – Get Free Report) and Teleflex (NYSE:TFX – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.
Profitability
This table compares electroCore and Teleflex’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| electroCore | -33.46% | N/A | -74.21% |
| Teleflex | 13.51% | 10.57% | 4.96% |
Institutional and Insider Ownership
26.7% of electroCore shares are owned by institutional investors. Comparatively, 95.6% of Teleflex shares are owned by institutional investors. 7.8% of electroCore shares are owned by insiders. Comparatively, 0.7% of Teleflex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and price targets for electroCore and Teleflex, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| electroCore | 1 | 1 | 1 | 0 | 2.00 |
| Teleflex | 0 | 6 | 5 | 1 | 2.58 |
electroCore presently has a consensus price target of $18.00, indicating a potential upside of 223.74%. Teleflex has a consensus price target of $163.30, indicating a potential upside of 5.83%. Given electroCore’s higher probable upside, analysts clearly believe electroCore is more favorable than Teleflex.
Earnings and Valuation
This table compares electroCore and Teleflex”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| electroCore | $32.03 million | 1.60 | -$13.97 million | ($1.39) | -4.00 |
| Teleflex | $2.26 billion | 2.71 | -$905.64 million | $8.23 | 18.75 |
electroCore has higher earnings, but lower revenue than Teleflex. electroCore is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
electroCore has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Teleflex has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.
Summary
Teleflex beats electroCore on 11 of the 15 factors compared between the two stocks.
About electroCore
electroCore, Inc. (NASDAQ: ECOR) is a commercial-stage medical device company focused on bioelectronic medicine and non-invasive vagus nerve stimulation (nVNS). Its technology is designed to stimulate the vagus nerve through the neck without requiring surgery or implanted components. The company’s primary prescription product is gammaCore, a handheld nVNS device used for the acute treatment of pain associated with migraine and episodic cluster headaches in adults. electroCore also markets consumer-oriented products, including Truvaga, a handheld vagus nerve stimulation device positioned for general wellness applications.
About Teleflex
Teleflex is a global medical technology company that develops, manufactures and markets single-use medical devices used by healthcare professionals in hospitals and other care settings. Its products support a range of procedures, including vascular access, anesthesia, critical care, surgery, urology and emergency medicine. The company’s offerings include vascular and interventional access devices, catheters, airway management products, surgical instruments and other devices used in diagnostic and therapeutic procedures.
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
